Company: TEM
Filing Date: 2025-02-24
Form Type: 10-K
Source: 0000950170-25-025603
Chunk: 27

Company: Tempus AI, Inc.
Filing Date: 2025-02-24
Form: 10-K
Item: Item 1
Chunk 27
---
 We believe our ability to launch Algos at scale is a key differentiator of our Platform.

Our Oncology Algos Portfolio

We believe our robust, multimodal dataset creates an opportunity for Algos that otherwise would not be possible and allows us to build AI models at scale, clinically validate them, and deploy the resulting Algos into clinical practice. We currently offer a suite of Algos in oncology, and have more in various stages of development. As of December 31, 2024, more than 80,000 molecular oncology Algos have been ordered with our various genomic assays. Most of the Algos we currently offer are part of our xR assay, and we do not bill separately for them. Some Algos will likely yield little to no reimbursement until their clinical utility is established or will be ordered separately with our existing NGS assays or diagnostics to enhance the actionable information for physicians, and some may obtain reimbursement at prevailing rates for comparable tests.

    Algo 
    Launch Year 
    Description 

    Oncology

    Tumor Origin (“TO”) Test
    2021
    •	Predicts the site of origin for cancer patients whose primary tumor site is unknown using tumor RNA expression results •	Intended use of the TO test is for cancers of unknown primary, or CUPs, and may help clinicians make more informed decisions where other clinical information like imaging and immunohistochemistry results do not provide a definitive diagnosis •	Uses information from analysis of nucleic acids by NGS performed as part of a separately ordered genomic or transcriptomic test •	Built using a large internal database of more than 20,000 annotated tumors with transcriptomic molecular data. By comparing the molecular profile (transcriptome) of the patient’s cancer with profiles of other cancers in our database, we can help pinpoint the origin of the patient’s cancer, potentially helping to inform the course of therapy •	For the year ended December 31, 2024, ordered on approximately 10% of our solid tumor profiles

    Homologous Recombination Deficiency (“HRD”) Test
     2020
    •	A DNA-based algorithmic test that helps identify if a patient has HRD, providing a comprehensive view into a patient’s ability to repair double-stranded DNA breaks •	HRD status can be used to identify patients who may be sensitive to PARP inhibitors and/or platinum-based chemotherapy •	Takes into account results from our solid tumor profiling, giving a full view into commonly mutated genes in the HR-path